701.85
-6.4(-0.90%)
Currency In USD
| Previous Close | 708.25 |
| Open | 710.2 |
| Day High | 717.61 |
| Day Low | 700.83 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 693 |
| Volume | 1.87M |
| Average Volume | 832,552 |
| Market Cap | 75.85B |
| PE | 17.36 |
| EPS | 40.44 |
| Moving Average 50 Days | 832.14 |
| Moving Average 200 Days | 982.38 |
| Change | -6.4 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,699.52 as of December 21, 2024 at a share price of $701.85. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,875.6 as of December 21, 2024 at a share price of $701.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
GlobeNewswire Inc.
Dec 19, 2024 12:00 PM GMT
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current stan
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2024 9:05 PM GMT
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
GlobeNewswire Inc.
Dec 17, 2024 12:00 PM GMT
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary bio